linjc16/ctgov huggingface dataset:
Efficacy of Celecoxib vs Placebo to Prevent Pain in a Paced Walk

Study Overview
=================
Brief Summary
-----------------
A paced 20-minute walk is a reproducible model for acute pain in knee osteoarthritis

Detailed Description
-----------------
This is a randomizd, placbo-controlled, crossover trial comparing a single dose of celecoxib to placebo measuring the time to onset of acute pain in a paced 20-minute walk. 40 subjects will be enrolled

Official Title
-----------------
A Double-blind, Placebo-controlled, Crossover Pilot Study of the Efficacy of Celecoxib 200 mg qd in Relieving Pain and Walking Dysfunction in Osteoarthritis of the Knee

Conditions
-----------------
Knee Osteoarthritis

Intervention / Treatment
-----------------
* Drug: celecoxib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Knee osteoarthritis by ACR clinical criteria Pain of at least 40 mm by VAS at baseline - Exclusion Criteria: Non-pregant, non-lactating Able to stop active arthritis medication for washout Cardiovascular risk factors Abnormal EKG -

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: celecoxib|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time to onset of severe pain |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time to onset of moderate pain |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pain, osteoarthritis
Buprenorphine Detox With Two Types of Treatment. BBD I - 10

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare overall treatment outcome between behavioral versus standard treatment types.

Official Title
-----------------
Buprenorphine Detox With Two Types of Treatment. BBD I

Conditions
-----------------
Opioid-Related Disorders

Intervention / Treatment
-----------------
* Drug: Buprenorphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Buprenorphine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Drug use |  |  | 
| Retention |  |  | 
| Weeks abstinent |  |  | 
| Weeks continuous abstinence |  |  | 
| Overall treatment outcome |  |  |
Isolated Growth Hormone Deficiency and Amennorrhea

Study Overview
=================
Brief Summary
-----------------
This is a case report of a 14-year old female with no menstruation history.

Detailed Description
-----------------
This is a case report of a 14-year-old with a chief complaint of inability to menstruate. Lab tests were done.

Official Title
-----------------
Isolated Growth Hormone Deficiency and Amennorrhea: Case Report

Conditions
-----------------
Growth Hormone Deficiency

Intervention / Treatment
-----------------
* Diagnostic Test: Hormone panel tests


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A single female participant with amenorrhea Exclusion Criteria: The study only included the above subject
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Hormone panel tests|Patient was subjected to a battery of hormone tests, including FSH, LH, estrogen, progesterone and growth hormone|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Growth hormone levels | Growth hormone levels assessed by hormone panel | 1 month after testing | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ISOLATED GROWTH HORMONE DEFICIENCY, AMENORRHEA
Laparoscopic Cholecystectomy for Acute Cholecystitis After 72 Hours of Symptoms

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the clinical outcomes of early versus delayed laparoscopic cholecystectomies for acute cholecystitis with more than 72 hours of symptoms.

Detailed Description
-----------------
In acute biliary cholecystitis, there was a dogma that patients should be operated within 72 hours of evolution. However, retrospective studies suggested that laparoscopic cholecystectomy even after 72 hours was safe. Moreover, some randomized controlled-trials did not found any differences in term of complications between early and delayed cholecystectomy, however none of these studies did separate patients according to the onset of symptoms. The aim of our present study was to compare the clinical outcomes of immediate versus delayed cholecystectomies for acute cholecystitis with more than 72 hours of symptoms.

Official Title
-----------------
Laparoscopic Cholecystectomy for Acute Cholecystitis: is the Rule of 72 Hours Still Actual?

Conditions
-----------------
Acute Cholecystitis, Cholecystectomy

Intervention / Treatment
-----------------
* Procedure: Laparoscopic cholecystectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: proven echographic cholecystitis Exclusion Criteria: pregnancy immunosuppression severe sepsis perforated cholecystitis peritonitis cholangitis acute pancreatitis

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Delayed<br>Laparoscopic cholecystectomy performed secondarily after an initial conservative treatment | Procedure: Laparoscopic cholecystectomy<br>* 3 trocars laparoscopic cholecystectomy<br>|
| Experimental: Early<br>Laparoscopic cholecystectomy performed directly after the initial diagnosis | Procedure: Laparoscopic cholecystectomy<br>* 3 trocars laparoscopic cholecystectomy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Adverse Event (Global Morbidity). | any adverse event occurring from time of diagnosis until the 30th postoperative day | 30 postoperative days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative Complications | postoperative complications graded according to Clavien classification | 30 postoperative days | 
| Length of Stay | total in hospital stay | 30 postoperative days |
Awareness to Osteopenia's Treatment by Bisphosphonate in Male Suffering From Prostate Cancer

Study Overview
=================
Brief Summary
-----------------
Patients with prostate cancer treated in outpatient clinics will be recruited by their urologist physician. Primary Objective: To evaluate the compliance in male patients with prostate cancer treated with Bisphosphonate and that suffered from Osteopenia/osteoporosis. Secondary objectives: To evaluate the compliance of family physicians to prescribe Bisphosphonate for patients upon recommendation by Urologists. To evaluate the overall number of patients treated by Bisphosphonate in the out-patient clinics, To evaluate incidence of osteopenia/osteoporosis in this study population.

Official Title
-----------------
Title: Increase Awareness to Osteopenia/Osteoporosis Treatment of Patients With Prostate Cancer, by Bisphosphonate Therapy - Registry.

Conditions
-----------------
Osteoporosis, Prostate Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Man with Prostate Cancer Men ≥70 years old or ≥60 years old treated by LH-RH agonist for at least 2 years or Man who was diagnosed in the past with Osteopenia/osteoporosis Osteopenia/osteoporosis proven by bone density test. Exclusion Criteria: Creatinine clearance < 30ml/min Hypercalcemia Actual treatment by Bisphosphonate or steroids Hypersensibility to Bisphosphonate or any contraindication to its use. Metastatic prostate Cancer Patients not suitable for compliance. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the compliance in male patients with prostate cancer treated with Bisphosphonate and that suffered from Osteopenia/osteoporosis. |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the compliance of family physicians to prescribe Bisphosphonate for patients upon recommendation by Urologists. |  | 6 months | 
| To evaluate the overall number of patients treated by Bisphosphonate in the out-patient clinics |  | 6 months | 
| To evaluate incidence of osteopenia/osteoporosis in this study population. |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Osteoporosis, Prostate Cancer, Osteoporosis in male with Prostate Cancer
Paracetamol Versus Placebo in Conjunction With Strong Opioids for Cancer Pain

Study Overview
=================
Brief Summary
-----------------
National guidelines advocate the use of paracetamol in conjunction with strong opioids for cancer pain, despite a lack of evidence for its efficacy. Work is needed to examine the analgesic benefit of paracetamol in this large patient group. The investigators aim to establish if paracetamol in combination with strong opioids provides superior analgesia for cancer related pain over strong opioids alone.

Official Title
-----------------
A Double-blind Randomised Parallel Group Trial of Paracetamol Versus Placebo in Conjunction With Strong Opioids for Cancer Related Pain

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Drug: Placebo
* Drug: Paracetamol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 16 years and over Under palliative care/oncology service review Diagnosis of incurable cancer Clinician-predicted life expectancy >2 months Anticipated to be clinically stable for duration of study involvement Receiving daily regular strong opioids Able to take study drug/placebo in its current form Prescribed and taking paracetamol 1g four times a day Average pain >3 and <9 in past 24 hours Able to provide written informed consent Able to complete necessary assessments required as part of the trial Average NRS pain score stable (ie. maximum range of 1 point) for the three consecutive days prior to randomisation Exclusion Criteria: Pain which the clinician deems to be unstable Clinically significant renal or liver disease Weight less than 50kg Those whose pain is expected to change during the course of the study as a result of oncological or other treatments Co-enrolment in other drug trials Known to be pregnant or breast-feeding at the time of recruitment Previously enrolled in this study

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Paracetamol<br>Participants will take blinded Paracetamol (as they were taking before entering the study) | Drug: Paracetamol<br>* Study medication contains blinded paracetamol<br>|
| Placebo Comparator: Placebo<br>Participants will take blinded Paracetamol | Drug: Placebo<br>* Study medication contains blinded placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of participants with a 30% increase in total Brief Pain Inventory between day 0 and day 14 in the active drug group versus the placebo group. |  | 14 days |
Imaging Cerebral and Sub-cerebral Correlates of Meditative States

Study Overview
=================
Brief Summary
-----------------
Three groups of subjects are trained to practice mindfulness meditation, compassion meditation, or attend a health training control class. Individuals from each group will undergo structural and functional brain imaging before and after training. The hypothesis is that the compassion meditation group will show the largest changes in brain structure and function. In a second series of experiments, the subjects practicing a Tibetan meditation practice will be undergo MRI thermometry imaging to construct detailed three dimensional temperature maps of their bodies before, during, and after they perform this practice.

Detailed Description
-----------------
Structural (MRI) Imaging will be used to measure changes in cortical thickness in the pre and post training groups. Function (fMRI) Imaging will be used to measure changes in cortical and sub-cortical responses to a series of affectively controlled visual images, presented during scanning. MRI Thermometry Imaging will be used to construct three dimensional temperature maps of subjects while performing meditation in the scanner.

Official Title
-----------------
Imaging Cerebral and Sub-cerebral Correlates of Meditative States

Conditions
-----------------
Stress

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-65 for the mindfulness-compassion study Prior training in gtummo meditation for the gtummo study Exclusion Criteria: Previous experience with meditation for the mindfulness-compassion study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HealthEd,Minfdulness,Compassion<br>HealthEd receives training health education. Mindfulness receives training in mindfulness meditation. Compassion receives training in compassion meditation. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Advance Care Planning Notifications in General Inpatient Medicine

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the impact of and response by physicians on Hospital Medicine/General Internal Medicine service to a notification identifying seriously ill patients at high risk of death within 30 days as well as within 6 months in a cluster randomized control trial.

Official Title
-----------------
Advance Care Planning Notifications in General Inpatient Medicine

Conditions
-----------------
Advance Care Planning

Intervention / Treatment
-----------------
* Other: Notification system


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 18 years of age Clinician on the Hospital Medicine or General Internal Medicine Service at Duke University Hospital Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention<br> | Other: Notification system<br>* Email and page notification sent to clinicians for patients at high-risk of mortality in 30 days and 6 months<br>|
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of advance care planning notes as measured by electronic health record data |  | Up to 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of advance care planning codes billed as measured by electronic health record data |  | Up to 30 days | 
| Number of Palliative Care Consults (Inpatient/Outpatient) as measured by electronic health record data |  | Up to 90 days | 
| Number of patients discharged to hospice as measured by electronic health record data |  | Up to 30 days | 
| Number of patients' code status changed to Do-Not-Resuscitate as measured by electronic health record data |  | Up to 30 days | 
| Number of patient deaths as measured by electronic health record data |  | Up to 14 days | 
| Number of patient deaths as measured by electronic health record data |  | Up to 30 days | 
| Number of patient deaths as measured by electronic health record data |  | Up to 6 months | 
| Number of patient re-admitted to the hospital as measured by electronic health record data |  | Up to 30 days | 
| Number of patient re-admitted to the hospital as measured by electronic health record data |  | Up to 6 months | 
| Number of advance care planning paperwork filed as measured by electronic health record data |  | Up to 30 days |
Transcranial Magnetic Stimulation (rTMS) Accelerates the Response to Escitalopram in Major Depression

Study Overview
=================
Brief Summary
-----------------
A doubleblind randomised trial with active versus sham rTMS in combination with escitalopram in patients with prior treatment resistant depression in an acute 12 weeks trial with subsequent 24 weeks study phase with active versus placebo citalopram

Detailed Description
-----------------
In this study we aimed at investigating to what degree rTMS applied over the left dorsolateral cortex relieves depressive symptoms when the treament is combined with antidepressive medication. The study will also be able to supply knowledge on how long any possible effect of the rTMS treatment lasts. In the first 12 weeks of the trial participants are randomised to either rTMS combined with escitalopram or sham rTMS combined with escitalopram. rTMS is given daily for the first 3 weeks. The next phase is a relapse prevention study where the responders from the initial phase are randomised to either active or placebo escitalopram for 24 weeks.

Official Title
-----------------
Treatment of Therapy-Resistant Major Depression With Transcranial Stimulation rTMS in Combination With Escitalopram

Conditions
-----------------
Major Depression

Intervention / Treatment
-----------------
* Device: rTMS
* Device: TMS
* Device: rTMS
* Device: rTMS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major depression Hamilton score above 18 Age 18 to 75 Exclusion Criteria: Pregnancy og breastfeeding Mental retardation and organic brain disease Alcohol and substance abuse Metal implants in brain, pacemakers and other electronic implants

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: A<br>rTMS | Device: rTMS<br>* 15 treatments of rTMS active with a duration of 30 minutes each<br>Device: TMS<br>* Transcraniel Magnetic Stimulation active and sham<br>Device: rTMS<br>* active Transcranial Magnetic Stimulation<br>Device: rTMS<br>* daily for three weeks<br>|
| Sham Comparator: B<br>sham rTMS | Device: TMS<br>* Transcraniel Magnetic Stimulation active and sham<br>Device: rTMS<br>* active Transcranial Magnetic Stimulation<br>Device: rTMS<br>* daily for three weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| depression scores |  | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Transcranial magnetic stimulation (TMS), Major depression, treatment resistant major depression